Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New vaccine may beat bird flu before it starts
By Maggie Fox, Health and Science Editor Thu Aug 9, 7:50 PM ET
WASHINGTON (Reuters) - Researchers studying bird flu viruses said on Thursday they may have come up with a way to vaccinate people before a feared influenza pandemic.
Experts have long said there is no way to vaccinate people against a new strain of influenza until that strain evolves. That could mean months or even years of disease and death before a vaccination campaign began.
But a team at the National Institute of Allergy and Infectious Diseases in Maryland and the Emory University School of Medicine in Atlanta said they may have found a short-cut.
The vaccine might protect people against the mutation that would change the H5N1 avian flu virus from a germ affecting mostly birds to one that infects people easily, the NIAID's Dr. Gary Nabel and colleagues report in Friday's issue of the journal Science.
"If we can define what changes need to be made to make that jump then we can target the immune system to that spot on the virus," Nabel said in a telephone interview.
"It gives us a chance to develop vaccines or monoclonal antibodies ... to really work in a preemptive way to be prepared."
Monoclonal antibodies, often used against cancer, are engineered immune system proteins that specifically attack proteins on a tumor or, in this case, on the flu virus.
"While nobody knows if and when H5N1 will jump from birds to humans, they have come up with a way to anticipate how that jump might occur and ways to respond to it," National Institutes of Health Director Dr. Elias Zerhouni said in a statement.
LEARNING FROM DISASTER
H5N1 remains mainly a virus of birds, but experts fear it could mutate into a form easily transmitted from person to person and sweep the world. It has occasionally infected people, killing 192 people out of 319 known cases since 2003, according to the World Health Organization.
To better try and understand the threat, researchers have studied various strains of H5N1 and compared them to the worst known flu virus ever -- the H1N1 virus that killed anywhere between 50 million and 100 million people in 1918 and 1919.
They found a mutation that makes one strain of the H1N1 virus more easily infect birds, and another one prefer humans. It lies in the part of the virus that attaches to cells in the respiratory tract.
They then made the same alteration in an H5N1 virus, and vaccinated mice with some of this genetically engineered H5N1 DNA.
They found an antibody that could neutralize both types of H5N1 -- H5N1 adapted to birds, and an engineered form that would in theory prefer humans.
"It delivers a powerful blow against this virus and really hits it where it lives," Nabel said.
If a vaccine could be designed to protect people against viruses with this mutation, it might be used before a pandemic even started, Nabel said.
A monoclonal antibody could be used to treat people who were already infected, he added.
Companies are making human vaccines against H5N1, but they are designed using the current strain of the virus, which does not easily infect humans. Scientists fear they are a poor match for any form of the virus that may eventually affect people.
Nabel said his team was working on some possible vaccines using the new approach.
10-Q out-from another poster:
By: joecris_us
09 Aug 2007, 04:45 PM EDT
Msg. 13769 of 13772
Jump to msg. #
IT"S outForm 10-Q for UNIGENE LABORATORIES INC
9-Aug-2007
Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2006, including the financial statements and notes contained therein.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Form 10-Q contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. These forward-looking statements include statements about the following: our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the delay in obtaining or the failure to obtain regulatory approvals for our products and litigation. Factors that could cause or contribute to differences in results and outcomes include, without limitation, those discussed in "Risk Factors" below and in our Annual Report on Form 10-K for the year ended December 31, 2006, such as uncertain revenue levels, rapidly changing technologies, stock price volatility and other factors discussed in our various filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2006.
RESULTS OF OPERATIONS
Introduction
We are a biopharmaceutical company engaged in the research, production and delivery of small proteins, referred to as peptides, for medical use. We have a patented manufacturing technology for producing many peptides cost-effectively. We also have patented oral and nasal delivery technologies that have been shown to deliver medically useful amounts of various peptides into the bloodstream. We have two locations: a laboratory research facility with administrative offices in Fairfield, New Jersey and a pharmaceutical production facility in Boonton, New Jersey. Our primary focus has been on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications. Our revenue for the past three years has primarily been derived from domestic sources. We have licensed worldwide rights to our manufacturing and delivery technologies for oral PTH to GSK. We have also licensed in the U.S. our nasal calcitonin product, which we have trademarked as Fortical, to USL. Fortical was approved by the FDA in August 2005. This is our first product approval in the United States. Both of these products are for the treatment of
Table of Contents
osteoporosis. We have also licensed worldwide rights to our patented manufacturing technology for the production of calcitonin to Novartis. We have an injectable calcitonin product, Forcaltonin® that is approved for sale in the European Union for osteoporosis indications. This product has not generated significant revenue. Our peptide products other than Fortical in the United States will require clinical trials and/or approvals from regulatory agencies and all of our products will require acceptance in the marketplace. There are risks that these clinical trials will not be successful and that we will not receive regulatory approval or significant revenue for these products. We compete with specialized biotechnology companies, major pharmaceutical and chemical companies and universities and research institutions. Most of these competitors have substantially greater resources than we do.
We generate revenue through licensing and supply agreements with pharmaceutical companies and by achieving milestones, product sales and royalties from those agreements. Those agreements, to date, have not been sufficient to generate all of the cash necessary to meet our needs. In addition, there are risks that current agreements will not be successful and that future agreements will not be consummated. We have tried to mitigate these risks by developing additional proprietary technologies and by pursuing additional licensing opportunities but there is no guarantee that these efforts will be successful. We are also seeking to generate additional revenue from sales of Fortical, but there is no guarantee that the product will generate significant additional revenue.
We have also generated cash from officer loans and from stock offerings. The officer loans have added debt to our balance sheet and, after being restructured in May 2007, will require repayment over a five-year period beginning in May 2010. Our various stock offerings have provided needed cash but it is uncertain whether they will be available in the future or, if available, on favorable terms. In March 2006, we completed the sale of a total of 4,000,000 shares of our common stock and a common stock warrant to purchase up to 1,000,000 shares of our common stock to Magnetar pursuant to a common stock purchase agreement. The five-year warrant is exercisable immediately at an exercise price per share of $4.25. We received gross proceeds of $13,000,000 before expenses of approximately $250,000.
The current need of major pharmaceutical companies to add products to their pipeline is a favorable trend for us and for other small biopharmaceutical companies. But this need is subject to rapid change and it is uncertain whether additional major pharmaceutical companies will have interest in licensing our products or technologies.
Revenue
Revenue is summarized as follows for the three-month and six-month periods ended
June 30, 2007 and 2006:
Three Months Ended June 30, Six Months Ended June 30,
2007 2006 2007 2006
Product Sales $ 3,091,677 $ - $ 7,115,409 $ -
Royalties 1,074,657 347,944 2,920,099 545,646
Licensing Revenue 347,690 189,189 578,546 378,378
Development Fees and other 204,188 18,854 432,430 18,854
$ 4,718,212 $ 555,987 $ 11,046,484 $ 942,878
Table of Contents
Revenue for the three months ended June 30, 2007 increased $4,162,000, or 749%, to $4,718,000 from $556,000 in the comparable period in 2006. Revenue for the six months ended June 30, 2007 increased $10,104,000, or 1,072%, to $11,046,000 from $943,000 in the comparable period in 2006. These increases were primarily due to an increase in market share for Fortical during 2007 resulting in an increase of Fortical sales of $2,300,000 and $4,915,000, respectively, for the three months and six months ended June 30, 2007 compared to the comparable periods in 2006. In addition, there was an increase in Fortical royalties of $727,000 and $2,374,000, respectively, for the three months and six months ended June 30, 2007 compared to the comparable periods in 2006. In the first half of 2006, because distributors' inventories at that time were sufficient to meet demand, we did not have any sales of Fortical to USL. Therefore, revenue for the three month and six month periods ended June 30, 2006 consisted primarily of Fortical royalties and licensing revenue. Royalty revenue is earned on sales of Fortical by USL and is recognized in the period Fortical is sold by USL. USL's royalty reports are based on their manufacturing quarters which prior to 2007 differed from calendar quarters by one month. Beginning in the first quarter of 2007, USL is providing royalty information for the last month of the calendar quarter. Therefore, our March 31, 2007 quarter (and only that quarter) included royalty revenue for four months, from December 2006 through March 2007. This quarter reported and future quarters will report three months of royalty revenue, corresponding to our calendar quarters. The effect of the inclusion of the fourth month of royalty revenue in the six months ended June 30, 2007 was an additional $536,000 of royalty revenue.
In addition, under the $2,500,000 supply agreement signed with Novartis in January 2007, we recognized $792,000 in product sales and $108,000 in development service fees for the three months ended June 30, 2007 and $2,200,000 in product sales and $300,000 in development service fees for the six months ended June 30, 2007. Also, a $5,500,000 milestone from Novartis, pursuant to our April 2004 licensing agreement, was achieved in February 2007 and received in April 2007. This milestone has been deferred and is being recognized over an 11-year period. Therefore, $125,000 and $167,000, respectively, of this milestone was recognized in the three month and six month periods ended June 30, 2007.
Licensing revenue represents the partial recognition of milestones and up-front payments received in prior years. Milestone revenue is based upon one-time events and is generally correlated with the development strategy of our licensees and is therefore subject to uncertain timing and not predictive of future revenue. Bulk peptide sales to our partners under license or supply agreements prior to product approval are typically of limited quantity and duration and also not necessarily predictive of future revenue. Additional peptide sales to GSK or Novartis are dependent upon their future needs, which we cannot currently estimate. We expect that sales revenue and royalty revenue could increase in future years if USL is able to continue to increase market share for Fortical. Sales revenue from Fortical in 2007 and future years will depend on Fortical's continued acceptance in the marketplace, as well as competition and other factors. It is uncertain whether or not Fortical will generate sufficient revenue for us to achieve profitability.
Costs and Expenses
Research, development and facility expenses primarily consist of personnel costs, supplies, outside testing and consulting expenses primarily related to our development efforts or activities related to our license agreements, as well as depreciation and amortization expense. All of our production and a portion of our research, development and facility costs are associated with our facility in Boonton, New Jersey, where costs are relatively fixed month-to-month. We allocate such costs to the manufacture of production batches for inventory purposes, to cost of goods sold, to inventory reserve or to research, development and facility activities, based upon the activities undertaken by the personnel in Boonton each period. Research, development and facilities expense increased 17% to
Table of Contents
$2,179,000 for the three months ended June 30, 2007 from $1,861,000 for the same period in 2006. Cost of materials and supplies increased $103,000, primarily due to the higher calcitonin production for inventory in the second quarter of 2006 which reduced 2006 material expense. There was higher calcitonin production for inventory in the second quarter and first half of 2006 due to the lack of Fortical sales in those periods. In addition, in the second quarter of 2007 outside consulting fees increased $119,000 and expenses for our oral calcitonin and oral PTH development programs increased $176,000. Research, development and facilities expense increased 26% to $4,303,000 from $3,404,000 for the six months ended June 30, 2007 as compared to the same period in 2006. Cost of materials and supplies increased $512,000, primarily due to the higher calcitonin production for inventory in the first half of 2006 which reduced 2006 material expense. In addition, in the first half of 2007, consulting fees increased $294,000, primarily due an increase of $170,000 in consultants' non-cash stock compensation. Expenses for our oral calcitonin and oral PTH development programs, primarily for outside testing services, increased $254,000. Research and development expenses should continue to increase in 2007, as compared to 2006, due to our continuing expenditures to further develop our oral calcitonin and oral PTH products, possibly including clinical trials; sponsorship of clinical trials in China; support for our SDBG program; and the conduct of feasibility studies on behalf of third parties.
Cost of goods sold varies by product and consists primarily of material costs, personnel costs, manufacturing supplies and overhead costs, such as depreciation and maintenance. Cost of goods sold for the three months and six months ended June 30, 2007 of $1,660,000 and $3,679,000, respectively, represented costs associated with our Fortical production for USL and our peptide production for Novartis. Cost of goods sold were $0 for the three months and six months ended June 30, 2006 due to the absence of sales in those periods. Cost of goods sold should continue to increase to support anticipated increases in Fortical sales, as well as possible increased peptide production to meet our partners' needs.
General and administrative expenses increased 33% to $1,919,000 from $1,440,000 for the three months ended June 30, 2007 as compared to the same period in 2006. The increase was primarily attributed to an increase of $399,000 in legal fees, mainly due to patent infringement litigation fees, and an increase of $68,000 in officers' compensation. General and administrative expenses increased 27% to $3,979,000 from $3,140,000 for the six months ended June 30, 2007 as compared to the same period in 2006. The increase was primarily attributed to an increase of $752,000 in legal fees, mainly due to patent infringement litigation fees; an increase of $232,000 in officers' compensation, due to salary increases as well as an increase of $81,000 in non-cash stock option compensation; and an increase of $113,000 in director/consultant fees mainly due to increases in office construction consultant fees and directors' non-cash stock option compensation. These were partially offset by a decrease in deferred compensation expense of $288,000, due to the initial charge in 2006 associated with the adoption of our deferred compensation plan in the first quarter of 2006. We expect general and administrative expenses to continue to increase in 2007, as compared to 2006, due to additional non-cash stock option compensation expense and to anticipated escalation of legal, personnel, insurance and other costs.
Other Income/Expense
Interest expense remained constant at $372,000 for the three months ended June 30, 2007 as compared to $371,000 for the three months ended June 30, 2006. Interest expense decreased 2% for the six months ended June 30, 2007 to $773,000 from $785,000 for the six months ended June 30, 2006 due to the loan restructuring described below. All periods were affected by the fact that in 2001 we did not make principal and interest payments on certain officers' loans when due. Therefore, the interest rate on certain prior loans increased an additional 5% per year and applied to both past due principal and interest. This additional interest for the three-month periods was
Table of Contents
approximately $106,000 for 2007 and $205,000 for 2006 and, for the six month periods, was approximately $337,000 for 2007 and $423,000 for 2006. On May 10, 2007, the outstanding principal and interest on these loans totaled $15,737,517 after an aggregate of $1,010,000 in repayments during 2007. On that date, interest rates ranged from 8.5% to 14.2% with certain loans having compound interest and the total of $15,737,517 in principal and interest was restructured as eight-year term notes with a fixed simple interest rate of 9% per annum. Required quarterly payments of principal and interest under these new notes begin in May 2010 over a five-year period. As a result of this loan restructuring, we expect interest expense to decline due to reduced interest rates as well as the lack of compounding and, in addition, we hope to make additional repayments in the future on this debt.
Net Loss
Net loss for the three months ended June 30, 2007 decreased approximately $1,708,000, or 57%, to $1,294,000 from $3,002,000 for the corresponding period in 2006. This was due to increased revenue of $4,162,000, primarily from USL and Novartis, partially offset by an increase in operating expenses of $2,457,000, mainly from an increase in cost of goods sold of $1,517,000 due to the sales of Fortical to USL and peptide to Novartis. Net loss for the six months ended June 30, 2007 decreased approximately $4,706,000, or 75%, to $1,538,000 from $6,244,000 for the corresponding period in 2006. This was due to increased revenue of $10,104,000, primarily from USL and Novartis, partially offset by an increase in operating expenses of $5,418,000, mainly from an increase in cost of goods sold of $3,536,000 due to the sales of Fortical to USL and peptide to Novartis. Net losses may continue unless we achieve recognizable revenue from milestones under our GSK and Novartis agreements, sign new revenue generating research, licensing or distribution agreements or generate sufficient sales and royalties from Fortical.
LIQUIDITY AND CAPITAL RESOURCES
At June 30, 2007, we had cash and cash equivalents of $6,765,000, an increase of $3,407,000 from December 31, 2006. The increase was primarily a result of Fortical sales and royalties received under our agreement with USL (see Note D), a $2,500,000 upfront payment from Novartis related to a supply agreement signed in January 2007 (see Note E), as well as an additional $5,500,000 received from Novartis in April 2007 for a milestone achieved in February 2007 (see Note E).
Our primary sources of cash have historically been (1) licensing fees for new agreements, (2) milestone payments under licensing or development agreements,
(3) bulk peptide sales under licensing or supply agreements, (4) stockholder loans and (5) the sale of our common stock. Since August 2005, we have also generated cash from sales and royalties on Fortical. We cannot be certain that any of these cash sources will continue to be available to us in future years. Licensing fees from new collaborations are dependent upon the successful completion of complex and lengthy negotiations. Milestones are based upon progress achieved in collaborations, which cannot be guaranteed, and are often subject to factors that are controlled neither by our licensees nor us. Product sales to our partners under these agreements are based upon our licensees' needs, which are sometimes difficult to predict. Sale of our common stock is dependent upon our ability to attract interested investors, our ability to negotiate favorable terms and the performance of the stock market in general and biotechnology investments in particular. Future Fortical sales and royalties will be affected by competition and further acceptance in the marketplace and could be impacted by any manufacturing, distribution or regulatory issues.
To satisfy our short-term liquidity needs, Jay Levy, our Chairman of the Board and an officer, Warren Levy and Ronald Levy, each a director and executive officer of Unigene, and another Levy family member, from time to time have made loans to us. At December 31, 2006, these short-term loans
Table of Contents
aggregated $8,105,000 with associated accrued interest of $8,081,180. At May 10, 2007, after principal payments of $1,010,000 during 2007, principal and interest were $7,095,000 and $8,642,517, respectively. This total owed aggregated $15,737,517 and, on May 10, 2007, was restructured as eight-year term notes with a fixed simple interest rate of 9% per annum. Required quarterly payments of principal and interest under these new notes begin in May 2010 over a five-year period. As of June 30, 2007, the aggregate principal and interest outstanding under these notes was $15,935,422. These loans are secured by security interests in our equipment, real property and/or certain of our patents.
We believe that in the short-term we will generate cash to apply toward funding our operations primarily through sales of Fortical to USL, royalties on USL's sales of Fortical and the achievement of milestones under our existing license agreements and, in the long-term, on sales and royalties from the sale of Fortical and other licensed products and technologies. We are actively seeking additional licensing and/or supply agreements with pharmaceutical companies for oral and nasal forms of calcitonin, as well as for other peptides, for our peptide manufacturing technology and for our SDBG technology. However, we may not be successful in achieving milestones under our current agreements, in obtaining regulatory approval for our other products or in licensing any of our other products or technologies.
In April 2002, we signed a licensing agreement with GSK for a value before royalties, bulk product sales and reimbursement for development expenses of up to $150,000,000 to develop an oral formulation of an analog of PTH currently in clinical development for the treatment of osteoporosis. PTH is in an early stage of development and it is too early to speculate on the probability or timing of a marketable PTH product (see Note C).
In November 2002, we signed an exclusive U.S. licensing agreement with USL for a value before royalties of $10,000,000 to market Fortical, our patented nasal formulation of calcitonin for the treatment of osteoporosis. During the first half of 2007, Fortical sales were $4,915,000 and Fortical royalties were $2,920,000. We expect Fortical sales and royalties to continue in 2007 and future years, but we cannot predict the levels of activity (see Note D).
In April 2004, we signed a worldwide licensing agreement with Novartis for a value before royalties of up to $18,700,000 to allow Novartis to manufacture calcitonin using our patented peptide production process. We will receive royalties on sales of any existing or future Novartis products that contain calcitonin manufactured by Novartis using our process. We plan to continue to develop our calcitonin products. If our oral calcitonin product is successfully developed, we would purchase calcitonin from Novartis, thereby eliminating our need to construct a second, larger-scale calcitonin manufacturing facility. Novartis will be conducting all future product development and clinical trials for its oral calcitonin product. Therefore, the anticipated completion date is outside our control and unknown to us. In the first quarter of 2007, under this agreement, we earned a $5,500,000 milestone payment from Novartis, which was received in April 2007, for the initiation of their oral calcitonin Phase III clinical study for osteoporosis (see Note E).
In January 2007, we signed a supply agreement with Novartis. Under this agreement, in March 2007, we received a $2.5 million payment to supply Novartis with specified quantities of bulk peptide necessary to support Novartis' development program for a novel osteoporosis treatment (see Note E).
We are engaged in the research, production and delivery of peptide-related products. Our primary focus has been on the development of manufacturing processes and delivery technologies for various peptide products for the treatment of osteoporosis, including nasal and oral calcitonin and oral PTH. We are also developing potential products in the area of SDBG. In general, we seek to
Table of Contents
develop the basic product or technology and then license the product or technology to an established pharmaceutical company to complete the development, clinical trials and regulatory process. As a result, we will not control the nature, timing or cost of bringing our products and technologies to market. Each of these products and technologies is in various stages of completion.
• For nasal calcitonin, a license agreement was signed in November 2002 with USL. Fortical was approved by the FDA and launched by USL in August 2005, generating sales and royalties.
• For oral calcitonin, we have two ongoing programs. Our external program is with Novartis and is currently in Phase III. The anticipated completion date is outside our control and unknown to us. For our internal program we are seeking a licensee to participate in our product's development. A small, short-term human study was recently initiated. The costs of future clinical trials may be borne by a future licensee depending upon our future financial resources. Because additional clinical trials are still necessary for our oral calcitonin product, it is too early to speculate on the probability or timing of a marketable oral calcitonin product. We will incur certain additional development costs.
• For oral PTH, a Phase I human trial, which commenced in June 2004, demonstrated positive preliminary results. However, PTH is in an early stage of development and it is too early to speculate on the probability or timing of a marketable oral PTH product. We signed a license agreement for this product with GSK in April 2002. We will incur certain additional development costs.
• Under the terms of a joint venture agreement in China with SPG, we are obligated to contribute up to $405,000 in cash after approval of its NDA (which was filed in China in September 2003) and up to an additional $495,000 in cash within two years thereafter. These amounts may be reduced or offset by our share of the entity's profits, if any. The approval of the NDA in China, and the timing of such approval, is uncertain.
• For our SDBG program, we have conducted various preclinical studies. This program is in a very early stage of development and therefore it is too early to speculate on the probability or timing of a license agreement for this technology or on a possible commercial product.
Due to our limited financial resources, any decline in Fortical sales, or delay in achieving milestones under our existing license agreements, or in signing new license or distribution agreements for our products, or loss of patent protection, may have an adverse effect on our cash flow and operations. In July 2006, we and USL jointly filed a patent infringement lawsuit against Apotex for infringement of our nasal calcitonin patent. If we are unsuccessful in our lawsuit, and if Apotex receives FDA approval and is able to launch its product, the launch of this generic product could have an adverse effect on our cash flow and operations. In addition, any material interruption or failure in manufacturing, marketing or distribution of Fortical will have an adverse effect on our cash flow and operations.
If USL cannot continue to successfully market Fortical, or if we are unable to achieve significant milestones or sales under our existing agreements and/or . . .
Sounds like a false press release heading, doesnt it?
Please post the financials for us showing SLJB is profitable. That is something we have all been waiting on. How did you get the AF's? Thank you.
Re news story yesterday warning of email scam-all of my emails came in attachments (which I did not open) but got this one today:
Inbox
Sent Messages
Drafts
Trash Can
Saved Mail
From : Loki Peska <Loki_Peska@longking.163.com>
Sent : Thursday, August 9, 2007 10:28 AM
To : <xxxxxxxxxtmail.com>
| | Junk E-Mail | Inbox
We've identified this mail as junk. Please tell us if we were right or wrong by clicking Junk or Not Junk
LIVE FROM THE STREET!
Sym: (PRTH)
Price: .088
Announces the Opening of Two New Stores by
(PINKSHEETS: PRTH) is pleased to announce that Puerto Rico 7, Inc. has
opened two new stores. The stores are recorded as Pinero II and Borinquen
Towers. Both locations were researched demographically to deliver above
average sales due to high traffic streets and communities directly
surrounding the stores. The Management team believes that the stores will
each quickly reach an annualized run rate of 1.2 Million dollars of sales.
IMAGINE IF YOU HAD THE CHANCE TO BUY A WAL-MART FRANCHISE IN MEXICO
RIGHT WHEN IT FIRST OPENED ITS DOORS THERE AND ALL YOU NEEDED WAS A
SMALL STAKE TO GET IN.
Hurry, we see this stock starting to make the turn NOW.
Wow, wait until the pumpers jump on this one,lol.
Medtronic to Acquire Biophan MRI Safety Technology for $11 Million
8:31a ET August 9, 2007 (Market Wire)
Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that the Company has entered into a definitive agreement with Medtronic, Inc. (NYSE: MDT) to acquire Biophan's MRI safety patents in a transaction worth $11 million in cash. The transaction is anticipated to close within 60 days.
Under the terms of the agreement, Biophan will transfer to Medtronic its MRI safety patent portfolio, which includes technologies that make medical devices, such as pacemakers, safe for use with MRI.
"Since our founding in 2000, our goal has been to develop and commercialize innovative technologies related to medical imaging safety, with a focus on the development of solutions for the contraindication between pacemakers and MRI machines," stated Mr. Guenter Jaensch, Chairman of Biophan's Board of Directors.
"Our technology has the potential to solve the problems that have prevented many people with pacemakers from having an MRI. We believe Medtronic has the experience and resources to bring our technology to market," stated Michael Weiner, President of Biophan.
Biophan will continue its efforts to develop technologies to enable visualization of clotting and restenosis in stents under MRI, which is not possible with today's stents. In addition, it will continue its collaboration with Myotech on the development of the Myotech Circulatory Support System, a novel device for the treatment of acute heart failure.
About Biophan Technologies, Inc.:
Biophan is dedicated to providing technologies that offer innovative and competitive advantages to the medical device industry. In addition, the Company is helping to commercialize Myotech's new cardiac support system which has significant potential to improve the treatment of many forms of heart disease. Biophan Technologies, Inc. holds a 45% interest in Myotech with rights to acquire a majority position, and is leading Myotech's business development efforts. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan, please visit our website at www.biophan.com
Beware penny buyers-the scammers are after you again today. I received 35+ new emails overnight from scammers listed in this post from yesterday.
Please help us all and forward your emails to following law enforcement agencies:
Forward Your Email Spams Here:
issuerservices@pinksheets.com
info@pinksheets.com
enforcement@sec.gov
spam@uce.gov
www.fbi.gov
www.usdoj.gov
More info at:
http://investorshub.advfn.com/boards/board.asp?board_id=7707
Basically a slap on the wrist by this judge. These scumbags need to be taught a lesson by being thrown in jail.
Yep, plenty of spammers here,lol.
Beware, penny buyers, the scammers are after you!
Giant 'pump-and-dump' spam scam hits computers by Adam Plowright
Wed Aug 8, 1:06 PM ET
PARIS (AFP) - Spammers have unleashed one of the biggest online stock manipulation campaigns in history in the last 24 hours, increasing global spam levels by 30 percent, a leading IT security company claimed Wednesday.
ADVERTISEMENT
Experts at SophosLabs have detected about 500 million emails containing advice to invest in Prime Time Stores Inc. -- an obscure US-listed group -- in a record-breaking example of the "pump-and-dump" spamming technique.
"Pump-and-dump" is when spammers buy shares, orchestrate a spam campaign promoting the company, then wait for a share price to rise before selling their stock for a profit.
"This particular campaign was first detected 24 hours ago in Germany and has caused a 30-percent rise in spam worldwide compared to typical levels," said Graham Cluley, senior technology consultant for Britain-based Sophos.
"This is staggering. It's one of the biggest spam campaigns we've ever seen," he told AFP in a telephone interview.
The email cites a company press release announcing the opening of shops by Prime Time Stores in Puerto Rico and goes on to say: "Imagine if you had the chance to buy a Wal-Mart franchise in Mexico right when it first opened its doors there and all you needed was a small stake to get in."
It adds: "Hurry, we see this stock starting to make the turn NOW. Big watch in effect for August 8, 2007!".
Prime Time Stores, which is the exclusive licensee for 7-Eleven convenience stores in Puerto Rico and the Caribbean, did not return calls when contacted by AFP.
The diversified company also has oil and gas, automotive, and mobile phone activities, according to its website.
The stock rose 2.35 percent in morning trade in the United States on Wednesday to 0.087 dollars, but gained 30 percent on Monday and 14.8 percent on Tuesday in the days running up to the detection of the campaign.
"It turns out that it's one of the kinds of spam that actually works," said John Levine, chair of US-based Anti-Spam Research Group.
"There are at least two academic studies that show that the share does go up and the bad guys make money."
Sophos estimates that "pump-and-dump" stock campaigns account for about 25 percent of all spam nowadays, up from less than 1.0 percent in January 2005.
Levine, who is also the author of hit book "Internet for Dummies," says the perpetrators are extremely difficult to catch despite efforts by stock market regulators and police.
"Spamming used to be about guys selling fake viagra from their basements," he said. "Now it's likely to be international crime gangs."
Cluley from Sophos said the share-ramping scams target small stocks, often worth a fraction of a cent, which require only a small increase to deliver big gains.
"They send out fake news about a tiny stock and there are so many day-traders out there that are ready to jump on the bandwagon," he said, referring to amateur investors who play the stock market from home.
The emails promoting Prime Time Stores stock, which are being propagated by thousands of virus-infected home computers whose owners are unaware, has a PDF attachment that contains the investment advice.
The use of a PDF file, a special document-friendly format, makes it easier for the email to slip through spam filters, Cluley said.
Levine has clear advice for anyone tempted to act on unsolicited investment advice sent via email.
"No stranger would ever give you a stock tip for your own good. It was true in the 1920s and it's just as true now," he said.
Giant 'pump-and-dump' spam scam hits computers by Adam Plowright
Wed Aug 8, 1:06 PM ET
PARIS (AFP) - Spammers have unleashed one of the biggest online stock manipulation campaigns in history in the last 24 hours, increasing global spam levels by 30 percent, a leading IT security company claimed Wednesday.
ADVERTISEMENT
Experts at SophosLabs have detected about 500 million emails containing advice to invest in Prime Time Stores Inc. -- an obscure US-listed group -- in a record-breaking example of the "pump-and-dump" spamming technique.
"Pump-and-dump" is when spammers buy shares, orchestrate a spam campaign promoting the company, then wait for a share price to rise before selling their stock for a profit.
"This particular campaign was first detected 24 hours ago in Germany and has caused a 30-percent rise in spam worldwide compared to typical levels," said Graham Cluley, senior technology consultant for Britain-based Sophos.
"This is staggering. It's one of the biggest spam campaigns we've ever seen," he told AFP in a telephone interview.
The email cites a company press release announcing the opening of shops by Prime Time Stores in Puerto Rico and goes on to say: "Imagine if you had the chance to buy a Wal-Mart franchise in Mexico right when it first opened its doors there and all you needed was a small stake to get in."
It adds: "Hurry, we see this stock starting to make the turn NOW. Big watch in effect for August 8, 2007!".
Prime Time Stores, which is the exclusive licensee for 7-Eleven convenience stores in Puerto Rico and the Caribbean, did not return calls when contacted by AFP.
The diversified company also has oil and gas, automotive, and mobile phone activities, according to its website.
The stock rose 2.35 percent in morning trade in the United States on Wednesday to 0.087 dollars, but gained 30 percent on Monday and 14.8 percent on Tuesday in the days running up to the detection of the campaign.
"It turns out that it's one of the kinds of spam that actually works," said John Levine, chair of US-based Anti-Spam Research Group.
"There are at least two academic studies that show that the share does go up and the bad guys make money."
Sophos estimates that "pump-and-dump" stock campaigns account for about 25 percent of all spam nowadays, up from less than 1.0 percent in January 2005.
Levine, who is also the author of hit book "Internet for Dummies," says the perpetrators are extremely difficult to catch despite efforts by stock market regulators and police.
"Spamming used to be about guys selling fake viagra from their basements," he said. "Now it's likely to be international crime gangs."
Cluley from Sophos said the share-ramping scams target small stocks, often worth a fraction of a cent, which require only a small increase to deliver big gains.
"They send out fake news about a tiny stock and there are so many day-traders out there that are ready to jump on the bandwagon," he said, referring to amateur investors who play the stock market from home.
The emails promoting Prime Time Stores stock, which are being propagated by thousands of virus-infected home computers whose owners are unaware, has a PDF attachment that contains the investment advice.
The use of a PDF file, a special document-friendly format, makes it easier for the email to slip through spam filters, Cluley said.
Levine has clear advice for anyone tempted to act on unsolicited investment advice sent via email.
"No stranger would ever give you a stock tip for your own good. It was true in the 1920s and it's just as true now," he said.
Experimental Biology and Medicine 232:847-851 (2007)
© 2007 Society for Experimental Biology and Medicine
--------------------------------------------------------------------------------
COMMENT
Ascorbic Acid Role in Containment of the World Avian Flu Pandemic
John T. A. Ely1
Radiation Studies, University of Washington, Seattle, Washington 98195
To whom requests for reprints should be addressed at 1 PO Box 1925, Palmerston North, New Zealand. E-mail: ely@u.washington.edu
Abstract
In this Comment, the ultimate intent is to increase survival of the anticipated global flu pandemic. The apparent failure of "medicine" to provide a completely understood and logically based biochemical prevention and treatment for all influenzas (and many other viral diseases) may be an unavoidable result of the evolving complexity of the H5N1 virus. However, clinical experience cited in all accounts, including the 2003 to 2006 period, suggest that: (i) ascorbic acid is not being administered to humans infected or at risk for influenza, and (ii) ascorbic acid is (mistakenly) believed to be a vitamin ("vitamin C"). Proper use of ascorbic acid as described here could provide effective containment for the flu pandemic.
Key Words: ascorbic acid • avian flu • immunity • hyperglycemia • refined diet
UGNE Q2 results on 8/10:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=21870159
FAIRFIELD, N.J.--(BUSINESS WIRE)--August 07, 2007
Unigene Laboratories, Inc. (OTCBB: UGNE) will release financial
results for the second quarter ended June 30 2007, before the market
opens on Friday, August 10th. The Company will also host a conference
call that morning, at 9:00 AM EDT to discuss its second quarter
financial results and to provide a Company update.
Unigene invites all those interested in hearing management's
discussion to join the call by dialing 866-585-6398 for participants
in the United States and 416-849-9626 for international participants.
A replay will be available for 7 days after the call and can be
accessed by dialing 866-245-6755 for participants in the United States
and 416-915-1035 for international participants. When prompted, enter
passcode #442914. You may also access the conference call via the web
at www.unigene.com and a link will be provided for you to listen in on
the call.
Go Odyssey-slam their (Spains) criminal actions-put their (govt crooks) criminal azzes in jail if possible.
Well looks like folks liked the koolaid-up 20% yesterday
No, I never open one unless I know who they are from. I suppose the spammer/scammers decided that most folks pay no attention (do not read) to an open stock spam so they are attempting to fool us with an attachment.
I continue to send all of them to spam@uce.gov and the obvious stock spams (with headings of "alert","investor",etc to sec,etc.
BCRX raises $55.3 mil:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=21850631
BioCryst Announces $65.3 Million Private Placement Financing
9:34a ET August 6, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed a definitive agreement to raise $65.3 million in a private placement of approximately 8.3 million shares of its common stock and warrants to purchase an additional approximately 3.2 million shares of common stock. The purchase price for the shares is $7.80 per share, the closing Nasdaq composite bid price for the company's common stock immediately preceding execution of the definitive agreement for the transaction and the exercise price for the warrants is $10.25. Investors in the financing will pay an additional purchase price equal to $0.125 for each share underlying the warrants. The closing of the private placement is subject to certain closing conditions.
Participants in the transaction include funds managed by Baker Brothers Investments, Kleiner Perkins Caufield & Byers, EHS Holdings, OrbiMed Advisors, Texas Pacific Group Ventures, and Stephens Investment Management.
"We are gratified by the strong support we received from this group of existing shareholders," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "The completion of the offering is a vote of confidence in the company's future and strengthens our balance sheet allowing us to bolster the company's fundamentals. BioCryst is now in a stronger position to execute on our plans, advancing key development programs through late-stage human trials while also mining our productive discovery engine for new compounds to move into the clinic."
About BioCryst
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
Forward-looking statements
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that the Phase II clinical trials of peramivir may not be successful, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of Fodosine(TM) in both T-ALL and CTCL may not be successful, that we may not resolve satisfactorily the particulate matter issue with the intravenous formulation of Fodosine(TM), that DHHS could reduce or eliminate funding for peramivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trials for Fodosine(TM) that are currently planned to be pivotal, that we may not be able to commence the proposed Phase III trial for peramivir within the time frame we currently expect or at all, that we may not be able to announce preclinical developments for additional compounds by year-end 2007 as currently proposed, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products, the conditions to closing the private placement may not be satisfied, and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.
Contact:
BioCryst Pharmaceuticals, Inc. Jonathan M. Nugent V.P. Corporate Communications (205) 444-4633
SOURCE BioCryst Pharmaceuticals, Inc.
Jonathan M. Nugent, V.P. Corporate Communications of BioCryst Pharmaceuticals, Inc., +1-205-444-4633
http://www.biocryst.com
Wow! PBLS selling $110MILLION of rocks per month?
Phoenix Announces Increase in KOMEX Contract
Market Wire - August 06, 2007 1:23 PM ET
Related Quotes
Symbol Last Chg
PBLS Trade 0.021 +0.0025
Quotes delayed at least 15 minutes
Phoenix Associates Land Syndicate (Phoenix) (PINKSHEETS: PBLS) today announced that its current total capacity to produce blended aggregate products has been purchased by KOMEX Export-Import.
Paul Alonzo, President and CEO of Phoenix, stated, "Phoenix currently has the ability to increase its production capacity to 2.5 million metric tons per month of blended aggregate products. After our last news release this past Friday on the 30 million metric ton order over five years, Mike O'Riley and Vince Promuto have agreed to honor KOMEX's request to purchase our entire production for five years, with a five year extension if desired."
Mr. Alonzo added, "This additional contract from KOMEX brings our committed orders to 150 million metric tons over five years or 2.5 million metric tons per month for 60 months. The total value of this five-year agreement as structured is $6.6 billion or $110 million per month."
The Company indicated that production will be ramped up during the balance of 2007 with full production by January 2008. Additional equipment is being purchased for crushing, excavating, and blending the blended aggregate products so as to meet production schedules.
Phoenix will be releasing equipment purchases, other acquisitions currently underway to increase current capacity, and also required transportation acquisitions to properly move the massive amounts of product to ports for export.
Phoenix will continue to keep its valued shareholders informed as further information comes available.
About Phoenix Associates
Phoenix Associates Land Syndicate is a holding company with assets in aviation, sand & gravel, soil products, land development, oil and natural gas, commodity brokering, plumbing, trucking, contract hauling, construction, swimming pool construction and construction-related industries.
Forward-Looking Statements
This press release contains statements that are "forward-looking" and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. Generally, the words "expect," "intend," "estimate," "will" and similar expressions identify forward-looking statements. By their very nature, forward-looking statements are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements, or that of our industry, to differ materially from those expressed or implied in any of our forward-looking statements. Statements in this press release regarding the Company's business or proposed business, which are not historical facts, are "forward-looking" statements that involve risks and uncertainties, such as estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made.
For More Information Contact:
Mike Mulshine
Osprey Partners
(732) 292-0982
osprey57@optonline.net
The email scammers are sending all my mail scam by attachments now. Anyone know why?
This is such a good deal on SLJB pps I cannot understand for the life of me why the pumpers are not buying entire float.
PainCare Signs Definitive Agreement to Sell The Gables Surgical Center in South Florida
Company to Net Approximately $4.4 Million from Sale
ORLANDO, Fla., Aug. 6 /PRNewswire-FirstCall/ -- PainCare Holdings, Inc. (AMEX: PRZ), one of the nation's leading providers of pain-focused medical and surgical solutions and services, today announced that it has signed a formal Definitive Agreement with Surgery Partners, LLC, providing for the sale of PainCare's controlling interest in PSHS Beta Partners, Ltd., d/b/a The Gables Surgical Center, located in Coral Gables, Florida. Subject to necessary regulatory approvals, the closing of the transaction will net PainCare approximately $4.4 million in cash proceeds. Actual terms and conditions related to this sale transaction will be fully detailed in a Form 8-K to be filed with the U.S. Securities and Exchange Commission.
"The cash raised from the sale of Gables Surgical Center will be applied towards further reducing our prevailing debt obligation to our noteholder while materially strengthening our overall financial footing," stated Randy Lubinsky, CEO of PainCare.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. Through Integrated Pain Solutions, the Company is engaged in pioneering the nation's first managed services organization that offers a multi-disciplinary healthcare network focused on the treatment of pain. For more information on PainCare Holdings, please visit www.paincareholdings.com.
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management. These forward-looking statements, which may include statements regarding our future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses, future operating margins and other future or expected performance, are subject to the following risks: the acquisition of businesses or the launch of new lines of business, which could increase operating expenses and dilute operating margins; the inability to attract new patients by our owned practices, the managed practices and the limited management practice; increased competition, which could lead to negative pressure on our pricing and the need for increased marketing; the inability to maintain, establish or renew relationships with physician practices, whether due to competition or other factors; the inability to comply with regulatory requirements governing our owned practices, the managed practices and the limited management practices; that projected operating efficiencies will not be achieved due to implementation difficulties or contractual spending commitments that cannot be reduced; and to the general risks associated with our businesses.
In addition to the risks and uncertainties discussed above you can find additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements in the reports that we have filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release represent our judgment as of the date of this release and you should not unduly rely on such statements. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in the filing may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
FOR MORE INFORMATION, PLEASE CONTACT:
Media Relations
Suzanne Beranek, APR, Beranek Communications, LLC
407-475-0763 or via email at suzanne@beranekcommunications.com
Investor/Shareholder Relations
Elite Financial Communications Group, LLC
Dodi Handy, President and CEO, or
Daniel Conway, Chief Strategist
407-585-1080 or via email at prz@efcg.net
SOURCE PainCare Holdings, Inc.
PainCare Signs Definitive Agreement to Sell The Gables Surgical Center in South Florida
Company to Net Approximately $4.4 Million from Sale
ORLANDO, Fla., Aug. 6 /PRNewswire-FirstCall/ -- PainCare Holdings, Inc. (AMEX: PRZ), one of the nation's leading providers of pain-focused medical and surgical solutions and services, today announced that it has signed a formal Definitive Agreement with Surgery Partners, LLC, providing for the sale of PainCare's controlling interest in PSHS Beta Partners, Ltd., d/b/a The Gables Surgical Center, located in Coral Gables, Florida. Subject to necessary regulatory approvals, the closing of the transaction will net PainCare approximately $4.4 million in cash proceeds. Actual terms and conditions related to this sale transaction will be fully detailed in a Form 8-K to be filed with the U.S. Securities and Exchange Commission.
"The cash raised from the sale of Gables Surgical Center will be applied towards further reducing our prevailing debt obligation to our noteholder while materially strengthening our overall financial footing," stated Randy Lubinsky, CEO of PainCare.
About PainCare Holdings, Inc.
Headquartered in Orlando, Florida, PainCare Holdings, Inc. is one of the nation's leading providers of pain-focused medical and surgical solutions and services. Through its proprietary network of acquired or managed physician practices, and in partnership with independent physician practices and medical institutions throughout the United States and Canada, PainCare is committed to utilizing the most advanced science and technologies to diagnose and treat pain stemming from neurological and musculoskeletal conditions and disorders.
Through its wholly owned subsidiary, Caperian, Inc., PainCare offers medical real estate and development services. Through Integrated Pain Solutions, the Company is engaged in pioneering the nation's first managed services organization that offers a multi-disciplinary healthcare network focused on the treatment of pain. For more information on PainCare Holdings, please visit www.paincareholdings.com.
This press release contains forward-looking statements that may be subject to various risks and uncertainties. Such forward-looking statements are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are made based on management's current expectations or beliefs as well as assumptions made by, and information currently available to, management. These forward-looking statements, which may include statements regarding our future financial performance or results of operations, including expected revenue growth, cash flow growth, future expenses, future operating margins and other future or expected performance, are subject to the following risks: the acquisition of businesses or the launch of new lines of business, which could increase operating expenses and dilute operating margins; the inability to attract new patients by our owned practices, the managed practices and the limited management practice; increased competition, which could lead to negative pressure on our pricing and the need for increased marketing; the inability to maintain, establish or renew relationships with physician practices, whether due to competition or other factors; the inability to comply with regulatory requirements governing our owned practices, the managed practices and the limited management practices; that projected operating efficiencies will not be achieved due to implementation difficulties or contractual spending commitments that cannot be reduced; and to the general risks associated with our businesses.
In addition to the risks and uncertainties discussed above you can find additional information concerning risks and uncertainties that would cause actual results to differ materially from those projected or suggested in the forward-looking statements in the reports that we have filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release represent our judgment as of the date of this release and you should not unduly rely on such statements. Unless otherwise required by law, we undertake no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise after the date of this press release. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in the filing may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.
FOR MORE INFORMATION, PLEASE CONTACT:
Media Relations
Suzanne Beranek, APR, Beranek Communications, LLC
407-475-0763 or via email at suzanne@beranekcommunications.com
Investor/Shareholder Relations
Elite Financial Communications Group, LLC
Dodi Handy, President and CEO, or
Daniel Conway, Chief Strategist
407-585-1080 or via email at prz@efcg.net
SOURCE PainCare Holdings, Inc.
Everyone seems to be wondering why Muslim terrorists are so quick to commit suicide.
Let's see now. . . . .
No Christmas
No television
No cheerleaders
No baseball
No football
No hockey
No golf
No tailgate parties
No Wal-Mart
No Home Depot
No pork BBQ
No hot dogs
No burgers
No chocolate chip cookies
No lobster
No shellfish, or even frozen fish sticks
No gumbo
No jambalaya
No Beer
Rags for clothes and towels for hats.
Constant wailing from the guy next-door because he's sick and there are no doctors.
Constant wailing from the guy in the tower.
More than one wife.
You can't shave.
Your wives can't shave.
You can't shower to wash off the smell of donkey cooked over burning camel dung.
The women have to wear baggy dresses and veils at all times.
Your bride is picked by someone else. She smells just like your donkey. But your donkey has a better disposition.
Then they tell you that when you die it all gets better! I mean, really, is there a mystery here?
Everyone seems to be wondering why Muslim terrorists are so quick to commit suicide.
Let's see now. . . . .
No Christmas
No television
No cheerleaders
No baseball
No football
No hockey
No golf
No tailgate parties
No Wal-Mart
No Home Depot
No pork BBQ
No hot dogs
No burgers
No chocolate chip cookies
No lobster
No shellfish, or even frozen fish sticks
No gumbo
No jambalaya
No Beer
Rags for clothes and towels for hats.
Constant wailing from the guy next-door because he's sick and there are no doctors.
Constant wailing from the guy in the tower.
More than one wife.
You can't shave.
Your wives can't shave.
You can't shower to wash off the smell of donkey cooked over burning camel dung.
The women have to wear baggy dresses and veils at all times.
Your bride is picked by someone else. She smells just like your donkey. But your donkey has a better disposition.
Then they tell you that when you die it all gets better! I mean, really, is there a mystery here?
UPDATE: U.S. Orders More Avian Flu Vaccine From GlaxoSmithKline
Dow Jones
August 03, 2007: 03:45 PM EST
BOSTON (Dow Jones) -- As part of the U.S. government's effort to stockpile vaccine in case of a pandemic flu outbreak, the Department of Health and Human Services has placed an order for additional doses of GlaxoSmithKline's avian flu vaccine.
In a statement, Glaxo (GSK) said HHS has placed an order for 22.5 million doses of its vaccine to prevent the H5N1 flu strain, commonly referred to as avian flu. The order is in addition to 5 million doses that the government ordered in November 2006
Glaxo also said that it has initiated Phase I/II clinical trials for its pre- pandemic vaccine. The studies will test the vaccine alone and in combination with one of Glaxo's adjuvant agents, which can boost the vaccine's strength. Results are expected early next year.
The vaccine ordered will be manufactured at Glaxo's Ste. Foy, Canada, plant. Glaxo added that the vaccine for the clinical trials will be produced at its facilities in Quebec. Glaxo acquired Canadian flu vaccine developer ID BioMedical in late 2005.
Glaxo hopes to begin a 4,400-patient Phase III trial for the vaccine later this year.
(END) Dow Jones Newswires
08-03-07 1545ET
Copyright (c) 2007 Dow Jones & Company, Inc.
http://money.cnn.com/news/newsfeeds/articles/djhighlights/200708031545DOWJONESDJONLINE000829.htm
PBLS up 21% on news:
Phoenix Associates Announces Acquisition, Additions to Staff and Major Contract
10:35a ET August 3, 2007 (Market Wire)
Phoenix Associates Land Syndicate (Phoenix) (PINKSHEETS: PBLS) today announced a number of significant developments related to its Aggregate Division, including the addition of Rock Concrete, the addition of Vince Promuto and Mike O'Riley to staff positions, and a major contract with KOMEX Import-Export for 30 million metric tons of Blended Aggregate Products.
Paul Alonzo, President & CEO of Phoenix, stated, "We are adding Rock Concrete, LLC, an international wholesaler of all types of aggregate products, to our Aggregate Division. Rock Concrete is being converted from an LLC to a Nevada corporation, and will be headquartered in Madisonville, Louisiana."
Mr. Alonzo added, "I am pleased to announce the additions of Vincent Promuto and Mike O'Riley to key staff positions within our Aggregate Division. Vince has joined our Company as Director of Acquisitions for mining and aggregate related equipment worldwide, while Mike O'Riley has assumed the position of Executive Vice President of International Operations."
Mr. Promuto's background is wide and impressive. Vince played professional football for the Washington Redskins for 11 years and was a Pro Bowl Selection two times during his pro career. After his professional football career, Vince held the position of Director of Public Affairs for the U.S. Drug Enforcement Agency and served as a special U.S. attorney in Washington, DC and New York. Vince had large investments in the waste management business in New York and now has interests in trucking and mining in the Northeastern United States.
Mr. O'Riley has a mining engineering degree and has worked in the mining business all around the globe. Mr. O'Riley comes from a background of five generations of mining expertise.
Mr. Alonzo commented further, "It is with the greatest of pleasure that we want our shareholders to know that because of our partnering in the aggregate business, Phoenix has received a purchase contract for Blended Aggregate Products from KOMEX Export-Import, a major export-import company headquartered in Poland, with offices in Canada, Switzerland, United Arab Emirates, and the United States. KOMEX is a worldwide user of blended aggregate products."
This initial KOMEX contract is for 30 million metric tons of blended aggregate products at $44/metric ton at the Company's production site in the USA. The delivery schedule as per the contract calls for a minimum of 500,000 metric tons per month for 60 months. These products are for delivery to Poland. This contract calls for a renewal for up to ten years.
KOMEX will post a three percent (3%) cash performance bond up front with Phoenix.
The method of payment to Phoenix under this contract is by irrevocable, revolving documentary letter of credit, confirmed by a world-class top 25 western European or American Bank, payable 100% at sight, against agreed shipping documents.
Phoenix indicated that additional contracts are currently being negotiated for the Aggregate Division, and that the Company is quickly expanding to an international level in oil and gas, and aviation as well. Many informative news releases will continue to be forthcoming so as to keep our valued shareholders informed of the Company's progress
PBLS up 21% and heavy vol on news:
Phoenix Associates Announces Acquisition, Additions to Staff and Major Contract
10:35a ET August 3, 2007 (Market Wire)
Phoenix Associates Land Syndicate (Phoenix) (PINKSHEETS: PBLS) today announced a number of significant developments related to its Aggregate Division, including the addition of Rock Concrete, the addition of Vince Promuto and Mike O'Riley to staff positions, and a major contract with KOMEX Import-Export for 30 million metric tons of Blended Aggregate Products.
Paul Alonzo, President & CEO of Phoenix, stated, "We are adding Rock Concrete, LLC, an international wholesaler of all types of aggregate products, to our Aggregate Division. Rock Concrete is being converted from an LLC to a Nevada corporation, and will be headquartered in Madisonville, Louisiana."
Mr. Alonzo added, "I am pleased to announce the additions of Vincent Promuto and Mike O'Riley to key staff positions within our Aggregate Division. Vince has joined our Company as Director of Acquisitions for mining and aggregate related equipment worldwide, while Mike O'Riley has assumed the position of Executive Vice President of International Operations."
Mr. Promuto's background is wide and impressive. Vince played professional football for the Washington Redskins for 11 years and was a Pro Bowl Selection two times during his pro career. After his professional football career, Vince held the position of Director of Public Affairs for the U.S. Drug Enforcement Agency and served as a special U.S. attorney in Washington, DC and New York. Vince had large investments in the waste management business in New York and now has interests in trucking and mining in the Northeastern United States.
Mr. O'Riley has a mining engineering degree and has worked in the mining business all around the globe. Mr. O'Riley comes from a background of five generations of mining expertise.
Mr. Alonzo commented further, "It is with the greatest of pleasure that we want our shareholders to know that because of our partnering in the aggregate business, Phoenix has received a purchase contract for Blended Aggregate Products from KOMEX Export-Import, a major export-import company headquartered in Poland, with offices in Canada, Switzerland, United Arab Emirates, and the United States. KOMEX is a worldwide user of blended aggregate products."
This initial KOMEX contract is for 30 million metric tons of blended aggregate products at $44/metric ton at the Company's production site in the USA. The delivery schedule as per the contract calls for a minimum of 500,000 metric tons per month for 60 months. These products are for delivery to Poland. This contract calls for a renewal for up to ten years.
KOMEX will post a three percent (3%) cash performance bond up front with Phoenix.
The method of payment to Phoenix under this contract is by irrevocable, revolving documentary letter of credit, confirmed by a world-class top 25 western European or American Bank, payable 100% at sight, against agreed shipping documents.
Phoenix indicated that additional contracts are currently being negotiated for the Aggregate Division, and that the Company is quickly expanding to an international level in oil and gas, and aviation as well. Many informative news releases will continue to be forthcoming so as to keep our valued shareholders informed of the Company's progress
It means a shareholder who "drinks" 100% of a company line (PR) whether they (company) are a group of scammers or simply totally incompetent mgt. The shareholder is usually a neophyte to pinkies or have bought in ,suffered a loss, and are being deceptive in pumping (stock manipulation) to attempt to get their money back.
Do you know anyone who does that?
BCRX to announce Aug. 9:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=21791186
BioCryst to Release Second Quarter 2007 Financial Results on Thursday, August 9, 2007
2:00p ET August 2, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its second quarter 2007 financial results will be released on Thursday, August 9, 2007. At 10:00 a.m. Eastern Time, BioCryst will host a conference call and live webcast. The call will be led by Jon P. Stonehouse, Chief Executive Officer, and Michael A. Darwin, Chief Financial Officer. BioCryst management will discuss the company's second quarter results and provide an update on the company's programs and business results.
To access the webcast via the internet, log on to http://www.biocryst.com. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternately, please call 1-800-817-4887 (U.S.) or 1-913-981-4913 (international). Telephone replay will be available. To access the replay, please call 1-888-203-1112 (U.S.) or 1-719-457-0820 (international) and dial the participant passcode 6741373. The webcast will be archived on http://www.biocryst.com
BioCryst Announces Realignment and Strengthening of the Company's Executive Management Team
7:00a ET July 26, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Stuart Grant will join the company's senior management team as Senior Vice President and Chief Financial Officer, effective August 27, 2007.
"These changes reflect the evolving needs of the company as we prepare for the next stage of our growth," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "Stuart's extensive experience with an established top tier biotechnology company, coupled with his financial strength and experience will add significantly to the senior management team. I am pleased that we have been able to attract someone of Stuart's caliber and integrity and I look forward to working with him as we move towards commercialization."
"I am delighted to be joining BioCryst at this exciting time in the Company's evolution," said Mr. Grant. "I am particularly attracted to BioCryst by the company's full pipeline, with its two advanced stage compounds, Peramivir and Fodosine(TM), and its productive discovery engine. I am also impressed by the energy and enthusiasm of the people at BioCryst, and I look forward to working with Jon and his team, leveraging my experience to help bring BioCryst to the next stage in its development."
Most recently, Mr. Grant held the position of Chief Financial Officer at The Serono Group with responsibility for driving growth and improving profitability. During his tenure with Serono, Mr. Grant held various senior Finance and Operating positions including Chief Financial Officer for U.S. Operations before his appointment to the position of CFO for the Group. Prior to joining Serono, Mr. Grant held various senior finance positions in the electronics industry in various European locations.
Mr. Michael A. Darwin will continue to serve as the company's Chief Financial Officer until the end of August, 2007 when he will assume the role of Vice President Finance reporting to Mr. Grant.
About BioCryst
BioCryst Initiates Phase II Clinical Trial to Evaluate Intravenous Peramivir in Patients Hospitalized With Influenza
7:00a ET July 24, 2007 (PR NewsWire)
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the initiation of a Phase II clinical trial in hospitalized patients using an intravenous (i.v.) formulation of peramivir, the company's lead influenza neuraminidase inhibitor. The trial will compare the efficacy and safety of intravenous peramivir to orally administered oseltamivir in patients who require hospitalization due to acute influenza.
"We are pleased to initiate this Phase II trial and we firmly believe that the availability of an intravenous formulation of peramivir will significantly improve options for treatment of persons with serious illness due to influenza and be a meaningful addition into the influenza market," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "The Centers for Disease Control estimates that over 200,000 persons are hospitalized and 36,000 persons die each year in the United States due to influenza and its complications. There is currently no drug for influenza that is available as an injection for hospital use and this intravenous formulation of peramivir holds particular promise in this indication."
The multicenter, randomized, double-blind study will compare the efficacy and safety of peramivir administered intravenously once daily for five days versus oral oseltamivir administered twice daily for five days in adults who are hospitalized with acute influenza. The current study will be conducted by investigators in both the Northern and Southern Hemispheres during the present and upcoming influenza seasons with enrollment expected in the US, Canada, Hong Kong, Singapore, Australia, New Zealand, and South Africa.
In addition to the trial announced today, BioCryst is currently conducting a separate Phase II trial using an intramuscular (i.m.) formulation of peramivir in individuals with influenza in the outpatient setting. Both studies are based on the positive Phase I clinical data obtained in 2006 and reported at the 46th Annual ICAAC meeting in September, 2006.
BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on January 3, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support Phase II and Phase III product development activities including manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst has retained all of its development and commercialization rights to peramivir worldwide except for in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & Co. in Japan, and Green Cross in Korea.
About Peramivir
Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors but are susceptible to peramivir in laboratory tests. At the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September, 2006, data were presented showing that injectable formulations of peramivir were safely administered to healthy subjects at daily doses up to approximately 600 mg. At the same meeting, animal data were presented showing peramivir promoted survival in animals infected with highly pathogenic strains of the H5N1 virus. Peramivir injection has received Fast Track designation from US FDA and the availability of an intravenous neuraminidase inhibitor may be important in treating patients hospitalized with severe and potentially life-threatening influenza. The availability of an injectable formulation of peramivir could ensure appropriate dosing which may be a concern with currently available oral or inhaled anti-influenza agents.
About Influenza
The influenza virus causes an acute viral disease of the respiratory tract. Unlike the common cold and some other respiratory infections, seasonal flu can cause severe illness, resulting in life-threatening complications. According to the Centers for Disease Control and Prevention, every year in the United States more than 200,000 people are hospitalized from flu complications, and about 36,000 people die from flu. Most at risk are young children, the elderly, and people with seriously compromised immune systems.
Avian influenza A viruses of H5N1 subtype are circulating among birds worldwide. The virus is considered extremely contagious in fowl. It is believed that all species of birds are susceptible to avian influenza, but domestic poultry, including chickens and turkeys, are among the more susceptible to the highly pathogenic strain. According to the World Health Organization, at least 318 people have contracted H5N1 avian influenza, of which at least 192 have died. Almost all of these infections are believed to have resulted from contact with infected poultry.
About BioCryst
Whoever utilizes software that can be used to originate telecommunications or other types of communications that are transmitted by the Internet without disclosing his identity and with intent to annoy, abuse, threaten, or harass any person who receives the communications shall be fined under title 18 or imprisoned not more than two years, or both.U.S.C. 223(h)(1)
UGNE begins new clinical trial:
http://investorshub.advfn.com/boards/read_msg.asp?message_id=21779221
Unigene Initiates Oral Calcitonin Clinical Study in Humans
8:01a ET August 2, 2007 (Business Wire)
Unigene Laboratories, Inc. (OTCBB: UGNE) has initiated a clinical study in the U.S. with its proprietary formulation of oral calcitonin for the treatment of osteoporosis.
The tablets used in the study utilize an improved solid dosage form of Unigene's Enteripep(R) oral delivery technology. The novel dosage form is the subject of a recently filed patent application and has already been shown in animal studies to deliver a more consistent dose of calcitonin while maintaining therapeutic blood levels of this peptide. An earlier version of the Enteripep technology has previously been used to successfully deliver calcitonin, parathyroid hormone (PTH) and several other therapeutically- important peptides in human and animal studies.
"Unigene has conducted a rigorous solid dosage form development effort over the last year to improve our proprietary delivery technology by reducing the variability of the dose to the patient, which has been a persistent problem for peptide oral delivery technologies," stated Dr. Warren Levy, President and CEO of Unigene. "We believe that the novel formulation not only achieves that goal, but also simplifies the manufacturing process. We also believe that the improved formulation should be applicable to the oral delivery of several other peptides that are currently in Unigene's pipeline."
Unigene previously licensed its Secrapep(R) manufacturing technology to Novartis for a second formulation of oral calcitonin that entered Phase III clinical studies earlier this year for osteoporosis and osteoarthritis.
About Unigene Laboratories, Inc.:
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical(R) to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are based upon Unigene Laboratories, Inc.'s management's current expectations, estimates, beliefs, assumptions, and projections about Unigene's business and industry. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These risks and uncertainties include the risks associated with the effect of changing economic conditions, trends in the products markets, variations in Unigene's cash flow, market acceptance risks, technical development risks and other risk factors detailed in Unigene's Securities and Exchange Commission filings.
SOURCE: Unigene Laboratories, Inc.
Unigene Investors: The Investor Relations Group Daniel Berg/Dian Griesel, Ph.D., 212-825-3210 or Media: Lynn Granito, 212-825-3210